New Opportunities to Identify, Prevent, and Manage Fibrosis in Children’s Interstitial and Diffuse Lung Disease - Enduring Module

Did you know that only 20% of surveyed physicians identified themselves as confident in most areas of diagnosing, understanding evidence based treatment options and disease mechanisms for pulmonary fibrosis in our pediatric patients? The Childhood ILD (chILD) Network has identified these needs in the medical community and aim to significantly improve these statistics. chILD is a term used to describe over 200 rare conditions of children with diffuse and interstitial lung disease that can be associated with significant morbidity and mortality.

This module will breakdown the findings and highlights of a two-day, interdisciplinary, hybrid course held in February, 2023 in Colorado featuring national thought leaders setting the stage to dive deeper into this complex, ever changing disease state. Please join us as we will show the outcome of a series of conversations on the outcomes of new studies and what the data means for the future of these rare conditions in our pediatric patient populations.

Commercial Support:

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals.

Target Audience

This activity is designed for Pediatricians, Internal Medicine-Pediatrics Physicians, Pediatric and Adult Pulmonologists, Rheumatologists, Oncologists, Immunologists, Pediatric Intensivists, Neonatologists, Radiologists, Pathologists, Advanced Practice Providers, Basic and Translational Scientists, and Clinical Research Coordinators.

Learning Objectives

  1. Explain the conditions associated with childhood interstitial and diffuse lung disease (chILD).
  2. List the diagnostic criteria and ongoing longitudinal follow up measurements in older children with pulmonary fibrosis.
  3. Identify the interaction needed amongst different health care professionals (pediatricians & different specialists) with the family and patient.
  4. Discuss the chILD patient registries across the world and identify resources to participate in them.

Additional Information

Course Contact: 
For any questions or concerns, please contact
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 
Children's Hospital Colorado
Aurora, CO
United States

Presenting Faculty:

Robin Deterding, MD
Professor of Pediatrics
Chief, Pediatric Pulmonary Medicine
Medical Director, The Breathing Institute
Medical Director, Children’s Hospital Colorado Innovation Center
Ed and Roxanne Fie Anderson Family Endowed Chair for Breathing

Emily DeBoer, MD
Associate Professor of Pediatrics
Medical Director, Multidisciplinary Aerodigestive Program
Breathing Institute, Children's Hospital Colorado

Peer Reviewer:

Bridget Raleigh, FNP-BC, AE-C
Associate Medical Director of Asthma Programs
The Breathing Institute/Pulmonary Medicine
Children's Hospital Colorado

Children’s Hospital Colorado is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Children’s Hospital Colorado designates this Enduring Material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

A certificate of attendance will be provided upon completion of this course.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance


Please login or register to take this course.

Required Hardware/software

You will need access to the internet, speakers or a headset to participate in this course.